CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting ...
By Nancy Lapid May 1 (Reuters) - We also report on a new use for artificial intelligence that could help eliminate some ...
New solutions include customized reagents that scale from bench to clinical trials, industrialized lentiviral vector ...
Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...
Immunofoco today announced the presentation of new preclinical data for its in vivo BCMA-targeting CAR-T candidate, IMV102, at the AACR Annual Meeting 2026. The data demonstrate that IMV102 achieved ...
This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...
Over the last decade, the cellular cancer immunotherapy known as CAR T-cell therapy has roared to the rescue of many blood cancer patients. The engineered immune cells revolutionized treatment of ...
Expanding CAR T beyond academic centers is primarily an access imperative, as travel distance and authorized-site ...
For decades, immunologists have explored CAR-T cell therapy as an effective tool to fight blood cancer. Increasingly, CAR-T cells are being explored as a potential silver bullet for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results